› Forums › General Melanoma Community › TAFINLAR or Zelboraf
- This topic has 9 replies, 3 voices, and was last updated 11 years, 6 months ago by
POW.
- Post
- Replies
-
-
- November 13, 2013 at 5:29 am
If the Zelboraf was working the tummors should haveat aminimum stopped growig. In most cases they do shrink and no neew tumors appear. If new tumors appear after shrinkage then the Zelboraf has stopped working.
-
- November 13, 2013 at 5:29 am
If the Zelboraf was working the tummors should haveat aminimum stopped growig. In most cases they do shrink and no neew tumors appear. If new tumors appear after shrinkage then the Zelboraf has stopped working.
-
- November 13, 2013 at 9:08 pm
Zelboraf (from Genentech) and Tafinlar (from GSK) both inhibit the BRAF protein containing a V600 mutation. They are very similar drugs with nearly identical properties but they are made by different manufacturers. Mekinist (also from GSK) inhibits a different protein (MEK). Zelboraf was FDA approved first– about 2 years ago– while Tafinlar and Mekinist were FDA approved in July.
Since they were developed by different, competing manufacturers, Genentech only did clinical trials on Zelboraf while GSK did clinical trials combining both Tafinlar and Mekinist. There have been no clinical trials of Zelboraf + Mekinist. Tafinlar + Mekinist has been shown to work in more people with fewer side effects than either Zelboraf or Tafinlar alone, especially if the patient did not receive any prior BRAF inhibitor treatment.
If it was me and I had a choice, I would go for the Taflinar + Mekinist combo. However, as with Zelboraf, melanoma tends to become resistant to Tafinlar after 6-9 months so it's a good idea to have a "Plan B" in mind. That usually means an immune-based treatment like Yervoy or anti-PD1 (which is still in clinical trials).
-
- November 13, 2013 at 9:08 pm
Zelboraf (from Genentech) and Tafinlar (from GSK) both inhibit the BRAF protein containing a V600 mutation. They are very similar drugs with nearly identical properties but they are made by different manufacturers. Mekinist (also from GSK) inhibits a different protein (MEK). Zelboraf was FDA approved first– about 2 years ago– while Tafinlar and Mekinist were FDA approved in July.
Since they were developed by different, competing manufacturers, Genentech only did clinical trials on Zelboraf while GSK did clinical trials combining both Tafinlar and Mekinist. There have been no clinical trials of Zelboraf + Mekinist. Tafinlar + Mekinist has been shown to work in more people with fewer side effects than either Zelboraf or Tafinlar alone, especially if the patient did not receive any prior BRAF inhibitor treatment.
If it was me and I had a choice, I would go for the Taflinar + Mekinist combo. However, as with Zelboraf, melanoma tends to become resistant to Tafinlar after 6-9 months so it's a good idea to have a "Plan B" in mind. That usually means an immune-based treatment like Yervoy or anti-PD1 (which is still in clinical trials).
-
- November 13, 2013 at 9:08 pm
Zelboraf (from Genentech) and Tafinlar (from GSK) both inhibit the BRAF protein containing a V600 mutation. They are very similar drugs with nearly identical properties but they are made by different manufacturers. Mekinist (also from GSK) inhibits a different protein (MEK). Zelboraf was FDA approved first– about 2 years ago– while Tafinlar and Mekinist were FDA approved in July.
Since they were developed by different, competing manufacturers, Genentech only did clinical trials on Zelboraf while GSK did clinical trials combining both Tafinlar and Mekinist. There have been no clinical trials of Zelboraf + Mekinist. Tafinlar + Mekinist has been shown to work in more people with fewer side effects than either Zelboraf or Tafinlar alone, especially if the patient did not receive any prior BRAF inhibitor treatment.
If it was me and I had a choice, I would go for the Taflinar + Mekinist combo. However, as with Zelboraf, melanoma tends to become resistant to Tafinlar after 6-9 months so it's a good idea to have a "Plan B" in mind. That usually means an immune-based treatment like Yervoy or anti-PD1 (which is still in clinical trials).
-
- November 13, 2013 at 5:29 am
If the Zelboraf was working the tummors should haveat aminimum stopped growig. In most cases they do shrink and no neew tumors appear. If new tumors appear after shrinkage then the Zelboraf has stopped working.
-
- You must be logged in to reply to this topic.